Identification of Ziyuglycoside II from a Natural Products Library as a STING Agonist
- PMID: 35293138
- DOI: 10.1002/cmdc.202100719
Identification of Ziyuglycoside II from a Natural Products Library as a STING Agonist
Abstract
Given the emerging pivotal roles of stimulator of interferon genes (STING) in host pathogen defense and immune-oncology, STING is regarded as a promising target for drug development. Cyclic dinucleotides (CDNs) are the first-generation STING agonists. However, their poor metabolic stability and membrane permeability limits their therapeutic application. In contrast, small-molecule STING agonists show superior properties such as molecular weight, polar character, and delivery diversity. The quest for a potent small-molecular agonist of human STING remains ongoing. In our study, through an IRF/IFN pathway-targeted cell-based screen of a natural products library, we identified a small-molecular STING agonist, Ziyuglycoside II, termed ST12, with potent stimulation of the IRF/IFN and NF-κB pathways. Furthermore, its binding to the C-terminal domain of human STING, detected by bio-layer interferometry, indicates that ST12 is a human STING agonist. Further Tanimoto similarity analysis with existing small-molecule STING agonists indicates that ST12 is a lead compound with a novel core structure for the further optimization.
Keywords: STING; natural products; small-molecule STING agonist; ziyuglycoside II.
© 2022 Wiley-VCH GmbH.
Similar articles
-
Conjugated STING agonists.Mol Ther Nucleic Acids. 2025 Mar 31;36(2):102530. doi: 10.1016/j.omtn.2025.102530. eCollection 2025 Jun 10. Mol Ther Nucleic Acids. 2025. PMID: 40291379 Free PMC article. Review.
-
STING activation and overcoming the challenges associated with STING agonists using ADC (antibody-drug conjugate) and other delivery systems.Cell Signal. 2025 Apr;128:111647. doi: 10.1016/j.cellsig.2025.111647. Epub 2025 Feb 6. Cell Signal. 2025. PMID: 39922441 Review.
-
Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.Eur J Med Chem. 2022 Aug 5;238:114482. doi: 10.1016/j.ejmech.2022.114482. Epub 2022 May 30. Eur J Med Chem. 2022. PMID: 35671593
-
The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy.Acta Pharm Sin B. 2022 Jan;12(1):50-75. doi: 10.1016/j.apsb.2021.05.011. Epub 2021 May 20. Acta Pharm Sin B. 2022. PMID: 35127372 Free PMC article. Review.
-
STING, a promising target for small molecular immune modulator: A review.Eur J Med Chem. 2021 Feb 5;211:113113. doi: 10.1016/j.ejmech.2020.113113. Epub 2020 Dec 18. Eur J Med Chem. 2021. PMID: 33360799 Review.
Cited by
-
Conjugated STING agonists.Mol Ther Nucleic Acids. 2025 Mar 31;36(2):102530. doi: 10.1016/j.omtn.2025.102530. eCollection 2025 Jun 10. Mol Ther Nucleic Acids. 2025. PMID: 40291379 Free PMC article. Review.
-
Therapeutic synthetic and natural materials for immunoengineering.Chem Soc Rev. 2024 Feb 19;53(4):1789-1822. doi: 10.1039/d3cs00805c. Chem Soc Rev. 2024. PMID: 38170619 Free PMC article. Review.
References
-
- G. N. Barber, Nat. Rev. Immunol. 2015, 15, 760-770.
-
- None
-
- J. Ahn, H. Konno, G. N. Barber, Oncogene 2015, 34, 5302-5308;
-
- G. Berger, M. Marloye, S. E. Lawler, Trends Mol. Med. 2019, 25, 412-427;
-
- J. B. Foote, L. A. Emens, Immunotherapy 2018, 10, 729-731.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
